Skip to Main Content

Oligoarticular juvenile idiopathic arthritis (oligoarthritis)

Oligoarticular juvenile idiopathic arthritis (oligoarthritis)

Oligoarticular juvenile idiopathic arthritis (JIA), also known as oligoarthritis, is the most common and often the mildest type of JIA. Oligoarticular JIA most commonly affects the knees, ankles, fingers, toes, wrists, elbows, and hips.

Oligoarticular JIA affects 4 or fewer joints during the first 6 months of the disease. Symptoms tend to be limited to joint swelling and pain. But it can also include uneven bone growth. This can lead to one leg being longer than the other. As it progresses, this type of JIA can develop into:

  • Persistent oligoarthritis, maintaining a mild level of disease, with 4 or fewer joints affected.
  • Extended oligoarthritis, affecting 5 or more joints after the first 6 months of disease, with a course much like polyarticular JIA.

Whole-body (systemic) symptoms (such as weakness, fatigue, and fever) are not common.

Children with oligoarticular JIA have a high risk for inflammatory eye disease. This can lead to blindness. Eye damage can occur without causing symptoms. So frequent eye exams are needed.

In the past, oligoarticular JIA was known as pauciarticular JIA.

Current as of: July 31, 2024

Author: Ignite Healthwise, LLC Staff

Clinical Review Board
All Healthwise education is reviewed by a team that includes physicians, nurses, advanced practitioners, registered dieticians, and other healthcare professionals.

This information does not replace the advice of a doctor. Ignite Healthwise, LLC, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

© 2024 Ignite Healthwise, LLC.

This information does not replace the advice of a doctor. Ignite Healthwise, LLC, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.